Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 3, 2010, Pages 722-728

  Bañez, Lionel L ^a,b   Klink, Joseph C ^a,b   Jayachandran, Jayakrishnan ^a,b   Lark, Amy L ^b   Gerber, Leah ^a,b   Hamilton, Robert J ^a,c   Masko, Elizabeth M ^a   Vollmer, Robin T ^a,b   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; INTRATUMORAL INFLAMMATION; MAJOR CLINICAL STUDY; MALE; ORGAN WEIGHT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; SEMINAL VESICLE;

AGED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 77949718840     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1074     Document Type: Article

References (20)

1. IMS. Retail Drug Monitor. http://www.imshealth.com/portal/site/ imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/? vgnextoid= 0d91d1707cce9110VgnVCM10000071812ca2RCRD& cpsextcurrchannel=1. Accessed June 1, 2009.
2. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
4. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
5. Haverkamp J, Charbonneau B, Ratliff TL. Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 2008;103:1344-53.
6. Blum DL, Koyama T, M'Koma AE, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 2008;14:7790-7.
7. Sooriakumaran P, Coley HM, Fox SB, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009;29:1483-8.
8. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and metaanalysis. Br J Cancer 2004;90:93-9.
9. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22: 2388-94.
10. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
11. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
12. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-7.
13. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-25.
14. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-32.
15. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Jr., Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
16. Irani J, Goujon JM, Ragni E, et al. Pathologist Multi Center Study Group. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 1999;54:467-72.
17. University of Michigan Guidelines for Clinical Care: Screening and Management of Lipids. http://cme.med.umich.edu/pdf/guideline/ lipids03.pdf. Accessed December 21, 2009.
18. Colli JL, Amling CL. Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol 2008;26: 627-33.
19. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hyper-cholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.
20. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.